Skip to main content

Table 1 Baseline characteristics of patients

From: Development and validation of a prognostic nomogram model in locally advanced NSCLC based on metabolic features of PET/CT and hematological inflammatory indicators

Variables

Training set

n = 104

Internal test set

n = 45

P*

External test set

n = 35

Age [years]

  

0.673

 

 Median (range)

61 (36–84)

60 (37–73)

 

65 (43–84)

Gender

  

0.273

 

 Male

72(69.2%)

27(60.0%)

 

26 (74.29%)

 Female

32(30.8%)

18(40.0%)

 

9 (25.71%)

Smoking

  

0.759

 

 Yes

56(53.8%)

23(51.1%)

 

24 (68.57%)

 No

48(46.2%)

22(48.9%)

 

11 (31.43%)

Tumor location

  

0.135

 

 Central

41(39.4%)

12(26.7%)

 

12 (34.29%)

 Peripheral

63(60.6%)

33(73.3%)

 

23 (65.71%)

T stage

  

0.296

 

 1

20(19.2%)

7(15.6%)

 

6 (17.14%)

 2

34(32.7%)

15(33.3%)

 

10 (28.57%)

 3

15(14.4%)

12(26.7%)

 

7 (20.00%)

 4

35(33.7%)

11(24.4%)

 

12 (34.29%)

N stage

  

0.954

 

 0

6(5.8%)

3(6.7%)

 

3 (8.57%)

 1

3(2.9%)

2(4.4%)

 

6 (17.14%)

 2

48(46.1%)

21(46.7%)

 

12 (34.29%)

 3

47(45.2%)

19(42.2%)

 

14 (40.00%)

cTNM stage

  

0.254

 

 IIIA

36(34.6%)

13(28.9%)

 

18 (51.43%)

 IIIB

68(46.4%)

32(71.1%)

 

10 (28.57%)

 IIIC

   

7 (20.00%)

Pathology

  

0.307

 

 ADC

58 (55.8%)

21 (46.7%)

 

13 (37.14%)

 SCC

46 (44.2%)

24 (53.3%)

 

22 (62.86%)

CEA [ng/ml]

11.66 [4.58, 39.4]

11.07 [4.77, 22.69]

0.755

6.05 [4.18, 11.21]

NSE [ng/ml]

14.83 [11.92, 18.41]

15.11 [12.32, 18.42]

0.711

18.92 [14.50, 21.94]

Cyfra21-1 [ng/ml]

4.04 [2.97, 6.76]

4.18 [3.02, 6.33]

0.962

5.25 [3.82, 13.52]

Lymphocyte [109 cells/L]

1.74 [1.28, 2.13]

1.78 [1.48, 2.23]

0.430

1.67 [1.35, 2.39]

Neutrophil [109 cells/L]

5.12 [3.95, 6.07]

4.71 [4.06, 6.00]

0.761

4.82 [3.18, 6.50]

Monocyte [109 cells/L]

0.51 [0.40, 0.69]

0.54 [0.41, 0.72]

0.315

0.54 [0.40, 0.82]

Platelet [109 cells/L]

269.00 [218.00, 328.00]

263.00 [191.00, 326.00]

0.872

258.00 [210.00, 302.00]

LMR

3.51 [2.40, 4.55]

3.17 [2.39, 4.34]

0.564

3.18 [2.05, 4.61]

NLR

2.86 [2.17, 3.86]

2.96 [2.01, 3.39]

0.699

2.73 [1.83, 4.06]

PLR

159.07 [110.70, 215.19]

144.74 [110.39, 186.49]

0.377

151.83 [105.09, 191.55]

SII

764.81 [532.54, 1088.50]

753.56 [454.07, 1108.47]

0.421

721.08 [417.97, 1067.48]

SUVmax

12.57 [8.71, 15.82]

11.64 [8.45, 15.22]

0.581

11.47 [9.65, 14.66]

SUVmean

5.08 [4.18, 6.32]

4.66 [3.90, 5.80]

0.076

5.92 [4.17, 6.96]

MTV

40.90 [14.98, 74.37]

26.82 [11.28, 59.01]

0.113

42.97 [17.15, 82.78]

TLG

210.00 [68.72, 437.71]

126.61 [45.01, 320.18]

0.085

272.54 [94.95, 673.87]

  1. *: Comparison of clinical characteristics between training, internal test, and external test sets
  2. Abbreviation: ADC: adenocarcinoma; SCC: squamous cell carcinoma; LMR: lymphocyte to monocyte ratio; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; SII: systemic immune-inflammation index; MTV: metabolic tumor volume; TLG: tumor lesion glycolysis